Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Private labeler receives tentative approval of its ANDA (75-598) for minoxidil 5% topical solution for men. Pharmacia's marketing exclusivity for Rogaine Extra Strength expires Nov. 14, after which Perrigo, Copley Pharmaceutical and Alpharma will join the fray (1"The Tan Sheet" Jan. 31, In Brief)
You may also be interested in...
Private label minoxidil
FDA tentatively approves Copley Pharmaceutical ANDA 75-619 for minoxidil 5% on Jan. 18. The reference drug, Pharmacia & Upjohn's Rogaine Extra Strength for Men, loses market exclusivity Nov. 14, 2000. The ANDA is the second for 5% minoxidil to be tentatively cleared by the agency; Alpharma received tentative approval on July 22. Perrigo also has filed an ANDA for the product
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands